Inhibrx Biosciences, Inc. (INBX) financial statements and ratios from SEC XBRL: revenue $1.30M (TTM), net margin -10773.5%, revenue growth 550.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $1.30M |
| Net Margin | -10773.5% |
| Revenue Growth (YoY) | 550.0% |
| EPS Growth (YoY) | -107.9% |
| FCF Growth (YoY) | -34.1% |
| Price / Sales | 1123.98 |
| FCF Yield | -16.7% |
| Altman Z-Score | 1.71 (distress) |
| Sector P/E (Healthcare) | 21.6 |
INBX overview · INBX earnings · INBX KPIs · INBX investor relations · INBX ownership · INBX peers · INBX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.